SCD1 inhibitor-treated cancer stem cells, when injected subcutaneously into athymic mice, displayed impaired in vivo tumor initiation capacity, delayed time-to-tumor formation, and reduced tumor burden. The gene discussed is SCD; the disease is neoplasm.